Rheumatoid Arthritis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The global rheumatoid arthritis treatment market is experiencing unprecedented growth, with the latest data indicating a market value of US$ 48 billion in 2024. Projections suggest that by the end of 2031, the market is expected to reach a staggering valuation of approximately US$ 75 billion. This substantial expansion is attributed to several key factors that are shaping the landscape of rheumatoid arthritis treatment.

High Disease Prevalence in Underdeveloped Regions

Rheumatoid arthritis is a leading cause of disability in regions like the Middle East and Africa, where prevalence rates are as high as 0.3% in Egypt and 0.4% in Lesotho. The underdeveloped but rapidly expanding economies in these areas offer significant growth potential for generic players in the market.

Regulatory Guidelines and Emergence of Novel Therapeutics

Recent regulatory changes, such as the Substitution Law in South Africa and Nigeria, as well as the growing purchasing power of the Moroccan government, have contributed to the expansion of the generic market. Additionally, the Food and Drug Administration Safety and Innovation Act of 2012 in the United States has introduced breakthrough therapy designations, fast-track approvals, and incentives for companies to develop innovative solutions, all of which are expected to drive market growth.

Innovative Approaches to Treatment

The emergence of novel treatment modalities, particularly mesenchymal stem/stromal cell (MSC)-based cell therapy, offers promising solutions for addressing persistent treatment challenges in rheumatoid arthritis. MSCs possess unique immunomodulatory characteristics, making them an attractive avenue for therapy development.

Challenges to Growth

Despite the remarkable growth prospects, the rheumatoid arthritis treatment market faces challenges that could hinder its expansion. The high cost of existing treatment options, particularly biologics, remains a significant barrier. Even with health insurance coverage, out-of-pocket costs for these medications can be exorbitant, limiting access for many patients.

Country-wise Insights

Booming U.S. Market

The United States is witnessing a booming market due to the rising prevalence of rheumatoid arthritis, increased use of disease-modifying antirheumatic drugs (DMARDs), advanced healthcare facilities, robust R&D activities, and substantial government investments in healthcare.

Lucrative Opportunities in Germany

Germany's growing pharmaceutical industry and increased investments in pharmaceutical research and development create a favorable environment for market expansion. The prevalence of rheumatic disorders in the country further fuels growth.

Japan as a Prominent Market

Japan's aging population and growing number of individuals with chronic diseases have led to rising healthcare costs. The implementation of a health technology assessment (HTA) program to regulate drug pricing is making Japan an attractive market for rheumatoid arthritis treatment.

Competitive Landscape

The rheumatoid arthritis treatment market is poised for substantial growth, driven by evolving regulatory landscapes, innovative therapies, and increasing disease prevalence. Despite challenges related to treatment costs, the market is expected to continue its upward trajectory, providing hope for millions of patients worldwide.

Key players in the global rheumatoid arthritis treatment market including:

Sanofi S.A.
Pfizer Inc.
Johnson & Johnson
AbbVie Inc.
Eli Lilly & Company
Amgen Inc.
Bristol-Myers Squibb Company
F. Hoffman-La Roche AG
Cipla, Inc.
Sun Pharmaceutical Industries Ltd.
Sobi Inc.
Novartis AG ( Sandoz)
UCB S.A.

Key Segments Covered in Global Rheumatoid Arthritis Treatment Market Research

Therapy:

Symptomatic Treatment
Intermediate Corticosteroid Therapies
Stem Cell Therapy
Disease Modifying Anti-rheumatic Drug (DMARD)
- Conventional DMARDs
- Biologic DMARDs

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Drug Stores

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Rheumatoid Arthritis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

3.1. Global Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 3.1.1. Key Highlights
  - 3.1.1.1. Symptomatic Treatment
  - 3.1.1.2. Intermediate Corticosteroid Therapies
  - 3.1.1.3. Stem Cell Therapy
  - 3.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 3.1.1.4.1. Conventional DMARDs
    - 3.1.1.4.2. Biologic DMARDs
3.2. Global Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 3.2.1. Key Highlights
  - 3.2.1.1. Hospital Pharmacy
  - 3.2.1.2. Retail Pharmacy
  - 3.2.1.3. Drug Stores
3.3. Global Rheumatoid Arthritis Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
- 3.3.1. Key Highlights
  - 3.3.1.1. North America
  - 3.3.1.2. Europe
  - 3.3.1.3. Asia Pacific
  - 3.3.1.4. Latin America
  - 3.3.1.5. Middle East & Africa

4. North America Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

4.1. North America Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 4.1.1. Key Highlights
  - 4.1.1.1. Symptomatic Treatment
  - 4.1.1.2. Intermediate Corticosteroid Therapies
  - 4.1.1.3. Stem Cell Therapy
  - 4.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 4.1.1.4.1. Conventional DMARDs
    - 4.1.1.4.2. Biologic DMARDs
4.2. North America Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 4.2.1. Key Highlights
  - 4.2.1.1. Hospital Pharmacy
  - 4.2.1.2. Retail Pharmacy
  - 4.2.1.3. Drug Stores
4.3. North America Rheumatoid Arthritis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 4.3.1. Key Highlights
  - 4.3.1.1. U.S. Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 4.3.1.2. U.S. Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 4.3.1.3. Canada Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 4.3.1.4. Canada Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
- 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

5.1. Europe Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 5.1.1. Key Highlights
  - 5.1.1.1. Symptomatic Treatment
  - 5.1.1.2. Intermediate Corticosteroid Therapies
  - 5.1.1.3. Stem Cell Therapy
  - 5.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 5.1.1.4.1. Conventional DMARDs
    - 5.1.1.4.2. Biologic DMARDs
5.2. Europe Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 5.2.1. Key Highlights
  - 5.2.1.1. Hospital Pharmacy
  - 5.2.1.2. Retail Pharmacy
  - 5.2.1.3. Drug Stores
5.3. Europe Rheumatoid Arthritis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 5.3.1. Key Highlights
  - 5.3.1.1. Germany Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.2. Germany Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.3. U.K. Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.4. U.K. Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.5. France Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.6. France Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.7. Italy Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.8. Italy Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.9. Turkey Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.10. Turkey Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.11. Russia Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.12. Russia Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 5.3.1.13. Rest of Europe Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 5.3.1.14. Rest of Europe Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
- 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

6.1. Asia Pacific Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 6.1.1. Key Highlights
  - 6.1.1.1. Symptomatic Treatment
  - 6.1.1.2. Intermediate Corticosteroid Therapies
  - 6.1.1.3. Stem Cell Therapy
  - 6.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 6.1.1.4.1. Conventional DMARDs
    - 6.1.1.4.2. Biologic DMARDs
6.2. Asia Pacific Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 6.2.1. Key Highlights
  - 6.2.1.1. Hospital Pharmacy
  - 6.2.1.2. Retail Pharmacy
  - 6.2.1.3. Drug Stores
- 6.2.2. BPS Analysis/Market Attractiveness Analysis
6.3. Asia Pacific Rheumatoid Arthritis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 6.3.1. Key Highlights
  - 6.3.1.1. China Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.2. China Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.3.1.3. Japan Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.4. Japan Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.3.1.5. South Korea Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.6. South Korea Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.3.1.7. India Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.8. India Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.3.1.9. Southeast Asia Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.10. Southeast Asia Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 6.3.1.11. Rest of Asia Pacific Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 6.3.1.12. Rest of Asia Pacific Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
- 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

7.1. Latin America Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 7.1.1. Key Highlights
  - 7.1.1.1. Symptomatic Treatment
  - 7.1.1.2. Intermediate Corticosteroid Therapies
  - 7.1.1.3. Stem Cell Therapy
  - 7.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 7.1.1.4.1. Conventional DMARDs
    - 7.1.1.4.2. Biologic DMARDs
7.2. Latin America Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 7.2.2. BPS Analysis/Market Attractiveness Analysis
7.3. Latin America Rheumatoid Arthritis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 7.3.1. Key Highlights
  - 7.3.1.1. Brazil Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 7.3.1.2. Brazil Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.3.1.3. Mexico Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 7.3.1.4. Mexico Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.3.1.5. Argentina Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 7.3.1.6. Argentina Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 7.3.1.7. Rest of Latin America Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 7.3.1.8. Rest of Latin America Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
- 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Rheumatoid Arthritis Treatment Market Outlook, 2018 - 2030

8.1. Middle East & Africa Rheumatoid Arthritis Treatment Market Outlook, by Therapy, Value (US$ Bn), 2018 - 2030
- 8.1.1. Key Highlights
  - 8.1.1.1. Symptomatic Treatment
  - 8.1.1.2. Intermediate Corticosteroid Therapies
  - 8.1.1.3. Stem Cell Therapy
  - 8.1.1.4. Disease Modifying Anti-rheumatic Drug (DMARD)
    - 8.1.1.4.1. Conventional DMARDs
    - 8.1.1.4.2. Biologic DMARDs
8.2. Middle East & Africa Rheumatoid Arthritis Treatment Market Outlook, by End User, Value (US$ Bn), 2018 - 2030
- 8.2.1. Key Highlights
  - 8.2.1.1. Hospital Pharmacy
  - 8.2.1.2. Retail Pharmacy
  - 8.2.1.3. Drug Stores
- 8.2.2. BPS Analysis/Market Attractiveness Analysis
8.3. Middle East & Africa Rheumatoid Arthritis Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
- 8.3.1. Key Highlights
  - 8.3.1.1. GCC Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 8.3.1.2. GCC Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.3.1.3. South Africa Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 8.3.1.4. South Africa Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.3.1.5. Egypt Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 8.3.1.6. Egypt Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.3.1.7. Nigeria Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 8.3.1.8. Nigeria Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
  - 8.3.1.9. Rest of Middle East & Africa Rheumatoid Arthritis Treatment Market by Therapy, Value (US$ Bn), 2018 - 2030
  - 8.3.1.10. Rest of Middle East & Africa Rheumatoid Arthritis Treatment Market by End User, Value (US$ Bn), 2018 - 2030
- 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Therapy vs by End User Heatmap
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Sanofi S.A.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Therapy Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Therapy Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Johnson & Johnson
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Therapy Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. AbbVie Inc.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Therapy Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Eli Lilly & Company
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Therapy Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Amgen Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Therapy Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Bristol-Myers Squibb Company
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Therapy Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. F. Hoffman-La Roche AG
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Therapy Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Cipla, Inc.
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Therapy Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Sun Pharmaceutical Industries Ltd.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Therapy Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Sobi Inc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Therapy Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Novartis AG ( Sandoz)
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Therapy Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations